Revogene C. difficile, in vitro diagnostic assay intended for use with the Revogene instrument, Catalog Number 410300 Recall
Revogene C. difficile, in vitro diagnostic assay intended for use with the Revogene instrument, Catalog Number 410300
FDA recall Class II
Ongoing
FDA lists this Class II recall for Revogene C. difficile, in vitro diagnostic assay intended for use with the Revogene instrument, Catalog Number 410300. Review the affected identifiers, reported reason and manufacturer instructions below.
Recall at a glance
- Recall number
- Z-1019-2026
- Recall classification
- Class II
- Enforcement status
- Ongoing
- Initiation date
- Dec 5, 2025
- FDA report date
- Jan 14, 2026
- Quantity in commerce
- 211 units
- Distribution
- See key details
- FDA cause
- Under Investigation by firm
What is being recalled?
Revogene C. difficile, in vitro diagnostic assay intended for use with the Revogene instrument, Catalog Number 410300
Affected model & UDI checker
Search the exact identifiers published for Z-1019-2026.
The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.
Affected products
| Model / catalog number | Product | Lot scope reported | UDI / GTIN |
|---|---|---|---|
| 410300 | Revogene C. difficile, in vitro diagnostic assay intended for use with the Revogene instrument, Catalog Number 410300 | Check source notice | Not specified |
| Not specified | Revogene C. difficile, in vitro diagnostic assay intended for use with the Revogene instrument, Catalog Number 410300 | Check source notice | 00840733102349 |
FDA code information
UDI-DI: 00840733102349; Lot Numbers: 410300U195, 410300U196, 410300U197, 410300U201
Why was this product recalled?
The affected lots show a decline in performance over time, which may lead to false-negative results.
What actions did Meridian Bioscience Inc take?
An "URGENT MEDICAL DEVICE CORRECTION" dated 12/1/25 was sent to customers. Required Actions: " Identify and segregate any remaining inventory of impacted product lots and suspend further use. " Destroy remaining inventory of impacted product lot in accordance with state, local, and/or federal regulations. o Contact Technical Service for replacement product. " Review previously obtained results from Revogene C. difficile listed Lots numbers. Any negative results obtained should be re-evaluated in conjunction with presented clinical findings to determine if retesting is required. " Complete and return the CONFIRMATION OF NOTIFICATION Form. Complete this form even if there is no remaining inventory. Actions to Be Taken By Meridian Bioscience, Inc.: Meridian Bioscience, Inc. will replace any unused inventory and provide support for any necessary retesting, including replacement test materials as needed. Contact Information: For any question regarding this notification please call Meridian Bioscience Technical Service at 1-800-343-3858, or email at [email protected].
Read the manufacturer action recorded by FDARecall timeline
Recall initiated by firm
FDA notice posted
FDA classification recorded
FDA enforcement report date
Related FDA submissions
No submission number with an exact verified relationship is linked in the retrieved recall notice.
FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.
Source and update history
- FDA recall notice Z-1019-2026
- openFDA enforcement record · Source release Nov 11, 2026 · Retrieved Nov 21, 2026
- openFDA device recall record · Source release Nov 19, 2026 · Retrieved Nov 21, 2026
- FDA enforcement data
First stored snapshot of this source.
- FDA device-recall notice
First stored snapshot of this source.
The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.
Our data sources and methodology